(DRNA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Analyst Ratings for

All Ratings (0)

Upgrades (0)

Downgrades (0)

Initiations (0)

date
Upside/Downside
Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert

undefined Questions & Answers

Q
What is the target price for undefined (DRNA)?
A

The latest price target for (: DRNA) was reported by Chardan Capital on December 9, 2021. The analyst firm set a price target for $38.25 expecting DRNA to fall to within 12 months (a possible NaN% downside). 13 analyst firms have reported ratings in the last year.

Q
What is the most recent analyst rating for undefined (DRNA)?
A

The latest analyst rating for (: DRNA) was provided by Chardan Capital, and downgraded their neutral rating.

Q
When is the next analyst rating going to be posted or updated for undefined (DRNA)?
A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of , and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for was filed on December 9, 2021 so you should expect the next rating to be made available sometime around December 9, 2022.

Q
Is the Analyst Rating undefined (DRNA) correct?
A

While ratings are subjective and will change, the latest (DRNA) rating was a downgraded with a price target of $28.00 to $38.25. The current price (DRNA) is trading at is $undefined, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.